Evidence map›Paper›PMID 39133385›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Cognitive performance and brain volume among survivors of pediatric hematological malignancies: a case-control study.

Amira M Osman, Amany M Ali, Heba A Sayed, Haisam Atta, Shimaa Ahmed, Nelly Alieldin, Mohamed A Abdelhamed, Khaled Saad, Azza Shibl

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amira M OsmanDepartment of Pediatric Oncology and Hematological Malignancies, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Amany M AliDepartment of Pediatric Oncology and Hematological Malignancies, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Heba A SayedDepartment of Pediatric Oncology and Hematological Malignancies, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Haisam AttaRadiology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Shimaa AhmedDepartment of Radiation Oncology and Nuclear Medicine, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Nelly AlieldinDepartment of Cancer Epidemiology and Biostatistics, National Cancer Institute, Cairo University, Cairo, Egypt.
Mohamed A AbdelhamedNeuropsychiatric Department, and Neuroepidemiology Lab, Faculty of Medicine, Assiut University, Assiut, Egypt.
Khaled SaadPediatric Department, Faculty of Medicine, Assiut University Children's Hospital, Assiut University Campus, Assiut, 71111, Egypt. ksaad8@yahoo.com.ORCID http://orcid.org/0000-0002-8473-6116
Azza ShiblDepartment of Pediatric Oncology and Hematological Malignancies, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCognitive dysfunction may be one of the hazardous late effects among survivors of pediatric hematological malignancies. Our study aimed to explore cognitive performance and assess the global and regional brain volume changes in survivors of hematological malignancies.

methodsThis case-control study was conducted on 68 survivors of hematological malignancies, with a median follow-up period of 2 years (ranging from 1 to 6.2 years). Stanford-Binet Test was used for cognitive assessment. A quantitative volumetric assessment of the brain was done using the NeuroQuant Brain Magnetic Resonance. Age and sex-matched 68 children were selected as a comparison group.

resultsCancer survivors showed significantly lower levels of IQ and their subtests than the control group. Global brain atrophy was observed in the majority of the survivors. Many risk factors significantly affected different IQ subtests, such as radiotherapy (RTH), high cumulative doses of methotrexate (MTX), and prednisone. At the same time, low white matter volume (WMV) was observed with higher cumulative doses of MTX and anthracyclines.

conclusionsHematological malignancies have a negative impact on cognition. Neurocognitive impairment and related brain changes were evident in those who received RTH, HDMTX, or high cumulative doses of steroids.

Indexed as

BrainCancer SurvivorsCognitionCognitive DysfunctionHematologic NeoplasmsAdolescentCase-Control StudiesChildChild, PreschoolFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMethotrexateOrgan SizeMethotrexateHematological malignanciesNeurocognitiveNeuroQuant MRIPediatricsVolumetric assessment

Identifiers

PMID39133385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.